NewLab Clinical Research   Report issue

Foundation Phase 1 Phase 2 Phase 3
Founded: St. John's Newfoundland Canada

Organization Overview

First Clinical Trial
2006
NCT00408187
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2011

Timeline

NOW
  • Now

Alternative names

Newlab Clinical Research Inc. | NewLab Clinical Research, St. John's, NF, A1B 3E1, Canada

Active Ingredients

Drugs in Phase 3 Trials (3)

brimonidine (alphagan) (1 trial)

cyclosporine (sandimmune) (1 trial)

voclosporin (Lupkynis) (1 trial)

Drugs in Phase 2 Trials (1)

nb-002 (1 trial)

Drugs in Phase 1 Trials (1)

dexbrompheniramine (disomer) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Erythema (Phase 3)

Onychomycosis (Phase 2)

Psoriasis (Phase 3)

Rosacea (Phase 3)

Tinea (Phase 1)

Tinea Pedis (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 5